Look out…the new CMI templates are finally here

SmartPHLEX

Author: Nicole Ten

TGA’s updated CMI templates and guidance is finally live on their website!

No new or additional content is required in the new templates. The intent was to revise the format to promote safe and effective use by improving the ease of identification and comprehension of information.

What’s new?

  • Introduction of an easy to understand, one-page CMI summary for critical information about the safe and effective use of the medicine. This is optional for Non-Prescription (OTC) medicines or for any medicines where the CMI is enclosed as a pack insert.
  • Separate templates for Prescription and Non-Prescription medicines, with the notable difference of having the summary page optional for the latter.
  • Presentation of side effects in tabular format, categorised into Less serious/Common and Serious/Rare, with side effects grouped by their effect on the body (e.g. bleeding related) and what to do for each type of side effect. This new format helps patients quickly identify serious side effects requiring immediate action.
  • Listing of active ingredient, excipients and potential allergens in a table for easy scanning.
  • Reference to the use of external hyperlinks (e.g. instructional videos / diagrams for device use) to enhance understanding.

When do I need to implement the new templates by?

The new templates take effect from 1 January 2021 for newly registered medicines. All previously registered medicines must be in the revised format by 30 December 2025.

Ready to download the updated templates? Click here.Contact us

Disclaimer:

This blog is intended to communicate PharmaLex’s capabilities which are backed by the author’s expertise. However, PharmaLex US Corporation and its parent, Cencora, Inc., strongly encourage readers to review the references provided with this article and all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto as the article may contain certain marketing statements and does not constitute legal advice. 

Scroll to Top